A multi-institutional study to assess adherence to lung stereotactic body radiotherapy planning goals

Medical Physics

Volumn 42, Issue 8, 2015, Pages 4629-4635

  Woerner, Andrew ^a   Roeske, John C ^a   Harkenrider, Matthew M ^a   Fan, John ^b   Aydogan, Bulent ^c   Koshy, Matthew ^c   Laureckas, Robert ^d   Vali, Faisal ^d   Campana, Maria ^a   Surucu, Murat ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b Edward Cancer Center   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d ADVOCATE CHRIST MEDICAL CENTER   (United States)

Author keywords

conformality; lung cancer; SABR; SBRT; stereotactic body radiotherapy

Indexed keywords

CLINICAL TRIAL; HUMAN; LUNG; LUNG NEOPLASMS; MULTICENTER STUDY; ORGANS AT RISK; PRACTICE GUIDELINE; PROCEDURES; RADIATION RESPONSE; RADIOSURGERY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING SYSTEM; RETROSPECTIVE STUDY; ROBOTIC SURGICAL PROCEDURE; STATISTICS AND NUMERICAL DATA;

GUIDELINE ADHERENCE; HUMANS; LUNG; LUNG NEOPLASMS; ORGANS AT RISK; PRACTICE GUIDELINES AS TOPIC; RADIOSURGERY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RETROSPECTIVE STUDIES; ROBOTIC SURGICAL PROCEDURES;

EID: 84965190987     PISSN: 00942405     EISSN: 24734209     Source Type: Journal    
DOI: 10.1118/1.4926551     Document Type: Article

References (22)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal, “Cancer statistics, 2014,” Ca-Cancer J. Clin. 64(1), 9–29 (2014).
2. J. P. Wisnivesky, M. Bonomi, C. Henschke, M. Iannuzzi, and T. McGinn, “Radiation therapy for the treatment of unresected stage I-II non-small cell lung cancer,” Chest 128(3), 1461–1467 (2005).
3. D. Ball, “Stereotactic radiotherapy for nonsmall cell lung cancer,” Curr. Opin. Pulm. Med. 14(4), 297–302 (2008).
4. X. Qiao, O. Tullgren, I. Lax, F. Sirzén, and R. Lewensohn, “The role of radiotherapy in treatment of stage I non-small cell lung cancer,” Lung Cancer 41(1), 1–11 (2003).
5. F. J. Lagerwaard et al., “Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer,” Int. J. Radiat. Oncol., Biol., Phys. 83(1), 348–353 (2012).
6. A. Bezjak et al., “Radiation Therapy Oncology Group. RTOG 0813 protocol information: Seamless phase I/II study of stereotactic lung radiotherapy (SBRT) for early stage, centrally located, non-small cell lung cancer (NSCLC) in medically inoperable patients” (2015). Available from: https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study =0813.
7. N. Boujelbene et al., “Stereotactic body radiation therapy in stage I inoperable lung cancer: From palliative to curative options,” Swiss Med. Wkly. 143, w13780 (2013).
8. L. Feuvert, G. Noel, J.-J. Mazeron, and P. Bey, “Conformity index: A review,” Int. J. Radiat. Oncol., Biol., Phys. 64(2), 333–342 (2006).
9. A. Chi, Z. Liao, N. P. Nguyen, J. Xu, B. Stea, and R. Komaki, “Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: Clinical implications,” Radiother. Oncol. 94(1), 1–11 (2010).
10. K. L. Stephans et al., “Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: Risk factors for late toxicity,” Int. J. Radiat. Oncol., Biol., Phys. 90(1), 197–202 (2014).
11. J. A. Forquer et al., “Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: Dose-limiting toxicity in apical tumor sites,” Radiother. Oncol. 93(3), 408–413 (2009).
12. N. E. Dunlap et al., “Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy,” Int. J. Radiat. Oncol., Biol., Phys. 76(3), 796–801 (2010).
13. M. A. Hallman et al., “Dose conformity predictors of symptomatic toxicity in patients treated with stereotactic body radiation (SBRT),” Int. J. Radiat. Oncol., Biol., Phys. 87(2), S53 (2013).
14. R. Timmerman et al., “Accreditation and quality assurance for radiation therapy oncology group: Multicenter clinical trials using stereotactic body radiation therapy in lung cancer,” Acta Oncol. 45(7), 779–786 (2006).
15. R. Timmerman et al., “Stereotactic body radiation therapy for inoperable early stage lung cancer,” JAMA, J. Am. Med. Assoc. 303(11), 1070–1076 (2010).
16. R. D. Timmerman et al., “An overview of hypofractionation and introduction to this issue of seminars in radiation oncology,” Semin. Radiat. Oncol. 18(4), 215–222 (2008).
17. G. M. Videtic et al., “Radiation Therapy Oncology Group. RTOG 0915 protocol information: A randomized phase II study comparing 2 stereotactic body radiation therapy (SBRT) schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer” (2015). Available from: https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study =0915.
18. H. C. Fernando and R. Timmerman, “American College of Surgeons Oncology Group Z4099/Radiation Therapy Oncology Group 1021: A randomized study of sublobar resection compared with stereotactic body radiotherapy for high-risk stage I non-small cell lung cancer,” J. Thorac. Cardiovasc. Surg. 144(3), S35–S38 (2012).
19. R. B. Barriger et al., “A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy,” Int. J. Radiat. Oncol., Biol., Phys. 82(1), 457–462 (2012).
20. I. S. Grills et al., “Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer,” J. Clin. Oncol. 28(6), 928–935 (2010).
21. C. L. Ong, D. Palma, W. F. A. R. Verbakel, B. J. Slotman, and S. Senan, “Treatment of large stage I-II lung tumors using stereotactic body radiotherapy (SBRT): Planning considerations and early toxicity,” Radiother. Oncol. 97(3), 431–436 (2010).
22. S. H. Benedict et al., “Stereotactic body radiation therapy: The report of AAPM Task Group 101,” Med. Phys. 37(8), 4078–4101 (2010).